

**THOMSON**  
★  
**DELPHION**

Tracking No Active T  
Select   

RESEARCH



PRODUCTS

INSIDE DELPHION

My Account

Search: Quick/Number Boolean Advanced Derwent

## The Delphion Integrated View

Buy Now:  PDF | More choices...Tools: Add to Work File:  Create new Work FileView: [Expand Details](#) | [INPADOC](#) | Jump to: [Top](#)  Go to: [Derwent](#) Email

Title: **WO9424297A1: DEFECTIVE RECOMBINANT ADENOVIRUSES FOR GENE THERAPY OF TUMOURS**[\[French\]](#)


Derwent Title: Defective recombinant adenovirus contg. anticancer heterologous DNA - partic. tumour repressor gene, anti-sense gene or gene that induces apoptosis, provides long lasting therapeutic effect.  
[\[Derwent Record\]](#)

Country: **WO** World Intellectual Property Organization (WIPO)

Kind: **A1** Publ.of the Int.Appl. with Int.search report [1](#)

Inventor: **PERRICAUDET, Michel;**  
**HADDADA, Hedi;**  
**MAY, Evelyne;**

Assignee: **RHONE-POULENC RORER S.A.**  
**PERRICAUDET, Michel**  
**HADDADA, Hedi**  
**MAY, Evelyne**  
[News, Profiles, Stocks and More about this company](#)



Published / Filed: **1994-10-27 / 1994-04-15**

Application Number: **WO1994FR0000421**

IPC Code: **C12N 15/86; A61K 48/00; C12N 15/12; C12N 15/11;**

ECLA Code: **C07K14/82; C12N15/861;**

Priority Number: **1993-04-22 FR1993000004745**

Abstract: Recombinant adenoviruses comprising a heterologous DNA sequence, preparation thereof, and use thereof for the treatment and/or prevention of cancer. [\[French\]](#)

[INPADOC](#) [Show legal status actions](#) Buy Now: [Family Legal Status Report](#)

Legal Status: **AT AU BE CA CH DE DK ES FI FR GB GR HU IE IT JP LU MC NL NO NZ PT SE US**

Designated Country: **Show 17 known family members**














Description  
Expand description  
**+ ADENOVIRUS RECOMBINANTS DEFECTIFS POUR LA THERAPIE GENIQUE DES TUMEURS**  
La présente invention concerne des vecteurs recombinants d'origine virale et leur utilisation pour le traitement des cancers. Plus particulièrement, elle concerne des adénovirus recombinants comportant une séquence d'ADN hétérologue dont l'expression dans une cellule se divisant anormalement permet d'inhiber au moins partiellement la division de ladite cellule. L'invention

















concerne également la préparation de ces vecteurs et les compositions pharmaceutiques les contenant.




- First Claim: Show all claims 1. Adénovirus recombinant défectif contenant une séquence d'ADN hétérologue dont l'expression dans une cellule cible permet d'inhiber au moins partiellement la division cellulaire. †

Forward  
References:

Go to Result Set: Forward references (33)


| Buy PDF   | Patent                    | Pub.Date   | Inventor               | Assignee  | Title   |
|---|---------------------------|------------|------------------------|---|---|
|    | <a href="#">US6805858</a> | 2004-10-19 | Zhang; Wei-Wei         | Board of Regents, The University of Texas System  | Methods for the adn of adenovirus p53   |
|    | <a href="#">US6797702</a> | 2004-09-28 | Roth; Jack A.          | Board of Regents, The University of Texas System  | Methods and comp comprising DNA dai agents and P53                            |
|    | <a href="#">US6783980</a> | 2004-08-31 | Fallaux; Frits Jacobus | Crucell Holland B.V.                              | Packaging systems recombinant adenov used in gene therap                      |
|    | <a href="#">US6747138</a> | 2004-06-08 | Dixit; Vishva M.       | Regents of the University of Michigan             | Methods and comp regulating Fas-asso apoptosis                                |
|  | <a href="#">US6740320</a> | 2004-05-25 | Zhang; Wei-Wei         | Board of Regents, The University of Texas System  | Recombinant P53 a methods and comp  |
|  | <a href="#">US6696423</a> | 2004-02-24 | Barsoum; James G.      | Biogen, Inc.                                      | Methods and comp therapies using gen encoding secreted p such as interferon-b |
|  | <a href="#">US6627189</a> | 2003-09-30 | Roth; Jack A.          | Board of Regents, The University of Texas Systems | Inhibition of cellular proliferation using r antisense molecule:              |
|  | <a href="#">US6602706</a> | 2003-08-05 | Fallaux; Frits Jacobus | Introgene B.V.                                    | Packaging systems recombinant adenov used in gene therap                      |
|  | <a href="#">US6562797</a> | 2003-05-13 | Dixit; Vishva M.       | The Regents of the University of Michigan         | Methods and comp regulating FAS-asso apoptosis                                |
|  | <a href="#">US6511847</a> | 2003-01-28 | Zhang; Wei-Wei         | Board of Regents, The University of Texas System  | Recombinant p53 a methods and comp  |
|  | <a href="#">US6482617</a> | 2002-11-19 | Yeh; Patrice           | Aventis Pharma S.A.                               | Viable contaminant adenoviruses, their and use                                |
|  | <a href="#">US6482803</a> | 2002-11-19 | Roth; Jack A.          | Board of Regents, The University of Texas System  | Modification of muta gene in tumors by r delivery of ribozyme                 |
|  | <a href="#">US6458578</a> | 2002-10-01 | Brough; Douglas E.     | GenVec, Inc.                                      | Recombinant cell lir adenoviral gene pro                                      |

|   |           |            |                         |   |  |
|---|-----------|------------|-------------------------|---|--|
|   |           |            |                         |   | and DEF-A, and/or I  |
|    | US6436700 | 2002-08-20 | Roth; Jack A.           | Board of Regents, The University of Texas Systems | Anti-sense p21 k-ra  |
|    | US6410029 | 2002-06-25 | Mukhopadhyay; Tapas     | Board of Regents, The University of Texas System  | 2-methoxyestradiol-apoptosis in cancer   |
|    | US6312946 | 2001-11-06 | Yeh; Patrice            | Rhone-Poulenc Rorer S.A.                          | Viable contaminant adenoviruses, their and use                                       |
|    | US6306652 | 2001-10-23 | Fallaux; Frits Jacobus  | IntroGene B.V.                                    | Packaging systems recombinant adenovirus used in gene therapy                        |
|    | US6238893 | 2001-05-29 | Hoeben; Robert Cornelis | Introgene B.V.                                    | Method for intracellular amplification   |
|    | US6210939 | 2001-04-03 | Gregory; Richard J.     | Canji, Inc.                                       | Recombinant adenovirus and methods of use  |
|   | US6200956 | 2001-03-13 | Scherman; Daniel        | Aventis Pharma S.A.                               | Nucleic acid-containing composition, preparation thereof                             |
|  | US6143290 | 2000-11-07 | Zhang; Wei-Wei          | The Board of Regents, University of Texas System  | Tumor regression by adenovirus expressing type p53                                   |
|  | US6069134 | 2000-05-30 | Roth; Jack A.           | Board of Regents, The University of Texas System  | Methods and compositions comprising DNA damage agents and p53                        |
|  | US6060238 | 2000-05-09 | Dixit; Vishva M.        | The Regents of the University of Michigan         | Method and compositions regulating apoptosis   |
|  | US6054467 | 2000-04-25 | Gjerset; Ruth A.        | Sidney Kimmel Cancer Center                       | Down-regulation of to enhance sensitivity mediated apoptosis                         |
|  | US6046007 | 2000-04-04 | Dixit; Vishva M.        | The Regents of the University of Michigan         | Method and compositions regulating apoptosis   |
|  | US6017524 | 2000-01-25 | Roth; Jack A.           | Board of Regents, The University of Texas System  | Inhibiting the growth of deficient tumor cells administering the p53                 |
|  | US6015665 | 2000-01-18 | Dixit; Vishva M.        | The Regents of the University of Michigan         | Method and compositions regulating apoptosis   |
|  | US5994106 | 1999-11-30 | Kovesdi; Imre           | GenVec, Inc.                                      | Stocks of recombinant replication-deficient free of replication-competent adenovirus |
|  | US5932210 | 1999-08-03 | Gregory; Richard J.     | Canji Inc.  | Recombinant adenovirus and methods of use  |
|  | US5824544 | 1998-10-20 | Armentano; Donna        | Genzyme Corporation                               | Adenovirus vectors therapy   |

|   |           |            |                  |  |  |
|---|-----------|------------|------------------|--|--|
|  | US5747469 | 1998-05-05 | Roth; Jack A.    | Board of Regents, The University of Texas System | Methods and compo comprising DNA dai agents and p53                      |
|  | US5707618 | 1998-01-13 | Armentano; Donna | Genzyme Corporation                              | Adenovirus vectors therapy   |
|  | US5637456 | 1997-06-10 | Roth; Jack A.    | The University of Texas, Board of Regents        | Rapid test for deter amount of functiona gene in a gene ther preparation |

Other Abstract  
Info:

CHEMABS 122(09)098807D CHEMABS 122(09)098807D DERABS C1994-341876 DE C1994-341876



Nominate this for the Gall

† Copyright © Univentio 2001-2003.

Copyright © 1997-2004  
The Thomson Corporation

[Subscriptions](#) | [Web Seminars](#) | [Privacy](#) | [Terms & Conditions](#) | [Site Map](#) | [Contact U](#)